EDDING GENOR

6998
1.5701.29% ( +0.020 )
Delay Closed: Nov 16, 16:08:00

Overview

EDDING GENOR (6998)

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical...

Open
1.570
High
1.575
Low
1.520
Prev. Close
1.550
Volume
764.50K
Turnover
1.20M
Avg Price
1.565
Bid/Ask Ratio
-35.48%
Amplitude
3.55%
52wk High
3.900
Volume Ratio
1.34
Turnover Ratio
0.04%
52wk Low
1.420
HK Mkt Cap
3.09B
Market CapHKD
3.09B
P/ETTM
12.24
P/EDynamic
Loss
P/EStatic
--
EPSTTM
0.128
EPSDynamic
-0.0771
EPSStatic
--
BVPS
2.33
P/B
0.67
HK Shares
1.97B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.97B
Min lot size
500
Currency
HKD

EDDING GENOR Analyst Rating

View more

Forecast & Rating

Aug 31, 2023
Price forecast
HK$1.44-7.99%
Forecast & RatingSell
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell100.00%

Daily Events

  1. Nov, 3

    Edding Genor fell 4.27% to HK$1.570, spiking to HK$1.640 in the morning session before sliding to an intraday low of HK$1.525 in the afternoon, on 1.48 million shares and HK$2.32 million turnover, a thin 0.08% turnover rate that amplified the move. Buybacks have continued: 500,000 shares for HK$810,000 on November 2 and another 500,000 for HK$785,000 on October 28, after several similar-sized repurchases from October 20, yet the bid offered limited support. ESMO 2026 first-in-human data showed GB268 monotherapy at a 19% response rate in the phase I breast cancer cohort, still early-stage. Q2 2026 revenue of HK$504.0 million fell 18.99% yoy, with a net loss of HK$38.0 million against a year-earlier profit, down 160.57%, net margin -7.54%, PE 12.27x and PB 0.67x. The stock is down 45.86% YTD, 59.74% below its 52-week high of HK$3.90 and only 10.56% above the HK$1.42 low, sitting under its MA20 of HK$1.641 and MA60 of HK$1.653. Continuous buybacks and a 0.67x PB offer some cushion, though.

  2. Oct, 26

    After ESMO 2026 first-in-human Phase I data for GB268, Edding Genor still faded an early rally, closing at HK$1.540, about 5.2% below the prior close of HK$1.625, having touched HK$1.635 at 09:58 BJ and HK$1.535 at 15:35 BJ. The 19% response rate in the Phase I breast cancer cohort and NMPA clearance for a Phase II colorectal trial contrast with Q2 2026 revenue of HK$504.0m (-18.99% yoy), a net loss of HK$38.0m (-160.57% yoy) and EPS of -0.0191. Buybacks were frequent, including 500,000 shares for HK$829,000 on October 20 alone, without lifting the stock. Price sits below MA20 of 1.671 and MA60 of 1.66, down 45% YTD, 59.1% under the 52-week high of HK$3.90 and 12.32% above the 52-week low of HK$1.42; PB is 0.69 and market cap HK$3.14bn. Though turnover of just 0.02% points to thin liquidity that can amplify intraday swings.

  3. Oct, 7

    Edding Genor reversed from its intraday high to close at HK$1.665, down about 2.1% from the prior HK$1.700, sliding from 1.700 in the morning session and touching 1.665 in the afternoon on just 243,500 shares, a turnover ratio of 0.01%. The pressure traces to fundamentals: the company swung to an H1 net loss of RMB 65.88 million with revenue down 23.1% to RMB 872.73 million, while Q2 net profit of -HK$37.99 million fell 160.6% year on year and the Jing Zhu Da sub-licensing deal collapsed after upstream license termination. Offsetting flows include continuous buybacks at HK$1.85-1.92 since October, a chairman plan to raise his stake, and August NMPA clearance for a Phase Ib/II trial of the trispecific breast cancer antibody GB268. The shares remain below MA20 (1.696) and MA60 (1.703), down 42.59% year to date and 61.64% below the 52-week high of HK$4.34. Though buybacks and pipeline progress provide partial offset.

  4. Sep, 25

    Edding Genor closed at HKD 1.665, opening down 0.6% before staging a dip-recovery pattern, hitting a fresh 52-week low of HKD 1.65 and rebounding to HKD 1.70. The stock has fallen 64.04% from its 52-week high of HKD 4.63 and is down 42.59% year-to-date, currently trading below both its MA20 (HKD 1.682) and MA60 (HKD 1.722). Fundamentals weakened further with H1 2026 net loss of ~HKD 75 million versus a year-ago profit, while revenue dropped over 18%. The company has been actively repurchasing shares around HKD 1.85-1.92, though the dramatic intraday rebound signals bargain-hunting support at these levels.

  5. Sep, 24

    Edding Genor (6998.HK) fell 5.3% in the morning session to HKD 1.70, as its H1 2026 net loss guidance of RMB 60-70 million (swinging from a year-ago profit) and an 18%+ revenue decline weighed on sentiment. The stock opened at HKD 1.79 and drifted to an intraday low of HKD 1.70, near its 52-week low of HKD 1.42, with YTD losses reaching 41.4%. The current price sits above its 20-day MA (HKD 1.674) but below the 60-day MA (HKD 1.725), indicating near-term support amid a medium-term downtrend. Recent share buybacks (up to 10% of issued shares) and the chairman's stake-boosting plan, along with NMPA approval for a Phase Ib/II trial of its trispecific breast cancer antibody GB268, provided some offset to the earnings warning.

News